Evidence map›Paper›PMID 40799319›Full record

ReviewJournal of Alzheimer's disease reports

Retinal manifestations and their diagnostic significance in Alzheimer's disease.

Surabhi D Abhyankar, Karis Little, Alan Stitt, Ashay D Bhatwadekar

Abstract readReview
In one paragraph

Review in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Surabhi D AbhyankarDepartment of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID https://orcid.org/0000-0001-9561-2410
Karis LittleThe Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry & Biomedical Science, Queen's University Belfast, Belfast, Northern Ireland, UK.ORCID https://orcid.org/0009-0007-3496-0041
Alan StittThe Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry & Biomedical Science, Queen's University Belfast, Belfast, Northern Ireland, UK.ORCID https://orcid.org/0000-0002-8647-9918
Ashay D BhatwadekarDepartment of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID https://orcid.org/0000-0003-0190-0505

Funding

miR-92a as a biomarker of diabetic retinopathyR01EY032080 · NEI · INDIANA UNIVERSITY INDIANAPOLIS · PI BHATWADEKAR, ASHAY D · 2021 to 2025
$2.6M
Retinal dysfunction in Alzheimer's disease mouse modelsR01EY027779 · NEI · INDIANA UNIVERSITY INDIANAPOLIS · PI BHATWADEKAR, ASHAY D · 2017 to 2021
$2.4M
NEI NIH HHS R01 EY027779NEI NIH HHS R01 EY032080
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative condition manifesting as cognitive decline, memory deterioration, and behavioral alterations. Late-onset AD accounts for most diagnosed cases, with the onset of symptoms usually occurring after 65 years. At present, there are no proven treatments that alter the course of AD. For early detection and intervention, it is crucial to understand the underlying mechanisms and identify promising biomarkers for AD. Research suggests that the pathological processes of AD initiate years before the emergence of noticeable symptoms, which makes the early diagnosis more challenging. While various biomarkers, such as cognitive tests, imaging, and biological markers in blood and cerebrospinal fluid, have been proposed for early detection, their reliability, as matched with symptomatic stages, varies significantly. As a component of the central nervous system, the retina has attracted attention as a potential site for studying AD-related changes. Studies from human and animal models have revealed structural, vascular, functional, and metabolic changes in the retina through the early phases of AD. Furthermore, advances in ophthalmic technologies have facilitated the identification and characterization of AD-related changes such as amyloid-β and tau-protein deposition. This review provides an overview and perspective on AD as they relate to the retina and highlights the importance of ocular changes as surrogates for understanding and diagnosing AD.

Indexed as

Alzheimer's diseaseamyloid-βneurodegenerationnon-invasive biomarkersocular imagingretinaretina-brain axisretinal biomarkersretinal pathologytau pathology

Identifiers

PMID40799319
PMCPMC12340214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.